Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.53 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL778917 | 0.85 | PTGS2 (0.49) | PTGS2PTGS1SLC6A4 | |
| SCHEMBL282516 | 0.85 | SOS1 (0.45) | PTGS2PTGS1SOS1 | |
| SCHEMBL778776 | 0.78 | PTGDR2 (0.42) | PTGS2PTGS1SLC6A4 | |
| SCHEMBL7363201 | 0.77 | PTGS2 (0.56) | PTGS2PTGS1CYP11B1CYP11B2 | |
| SCHEMBL28014796 | 0.76 | NPBWR1 (0.42) | SLC6A4 | |
| SCHEMBL283161 | 0.74 | MAOA (0.55) | SOS1SCN9ASLC6A4 | |
| SCHEMBL14959552 | 0.73 | MAOA (0.37) | PTGS2PTGS1SOS1SLC6A4 | |
| SCHEMBL14997968 | 0.73 | NPBWR1 (0.44) | SLC6A4 | |
| SCHEMBL11989282 | 0.73 | PPARG (0.40) | CYP11B1CYP11B2SLC6A4 | |
| SCHEMBL15904561 | 0.73 | HSD17B10 (0.45) | SOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140206865-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| EP-1511488-B1 | HUMAN ADAM-10 INHIBITORS | SYMPHONY EVOLUTION INC (US) | 2013-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206865-A1 | Human Adam-10 Inhibitors | ADAM10, MMP20, ADAM9 | PTGS2 651/4885PTGS1 167/4885SOS1 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.